中国麻风皮肤病杂志 ›› 2023, Vol. 39 ›› Issue (9): 661-663.doi: 10.12144/zgmfskin202309661

• 临床研究 • 上一篇    下一篇

单用度普利尤单抗治愈高龄大疱性类天疱疮一例

贾凤铭1,方梦1, 2,刘永霞1,刘红1   

  1. 1山东第一医科大学附属皮肤病医院(山东省皮肤病医院)，山东省皮肤病性病防治研究所，济南，250022；
    2山东大学，山东济南，250014
  • 出版日期:2023-09-15 发布日期:2023-09-05

Dupilumab alone successfully treated an elderly patient with bullous pemphigoid

JIA Fengming1, FANG Meng1,2, LIU Yongxia1, LIU Hong1   

  1. 1 Shandong Provincial Hospital for Skin Diseases ＆ Shandong Provincial Institute of Dermatology and Venereology，Shandong First Medical University ＆ Shandong Academy of Medical Sciences，Jinan 250022，China;
    2 Shandong University, Jinan 250014, China
  • Online:2023-09-15 Published:2023-09-05

PDF (PC)

84

摘要： 大疱性类天疱疮（bullous pemphigoid，BP）是常见的自身免疫性大疱性皮肤病，多发生于老年患者，常合并有多种神经系统疾病和血栓、栓塞病史，因此高龄BP患者应用糖皮质激素治疗具有很大的挑战性。本文报道单用度普利尤单抗成功治疗合并多系统慢性病史的高龄BP患者一例。91岁女性患者躯干、四肢红斑水疱伴痒半年，既往高血压病史2年余，心梗病史4年，脑梗病史2年。通过组织病理、免疫组化及血清抗体等检查，确诊为大疱性类天疱疮，BPDAI基线期评分18。给予度普利尤单抗皮下注射首剂600mg, 2周后次剂注射300mg治疗。3周后皮损基本消退，局部留色素沉着，BPDAI评分降至4。随访3个月，未见复发。

关键词: 大疱性类天疱疮, 度普利尤单抗

Abstract: Bullous pemphigoid (BP) is a common autoimmune bullous derma, which mainly occurs in the elderly patients, and such patients often have a history of multiple neurological diseases, thrombosis and embolism, so the application of glucocorticoids in the treatment of elderly BP patients is a great challenge. Herein, we report  a case of successful treatment of elderly BP patients complicated with multi-system chronic history with dupriuzumab alone.  A 91-year-old female presented with itching erythema, blister on the trunk and limbs for half a year. The patient had a history of hypertension for more than 2 years, myocardial infarction for 4 years and cerebral infarction for 2 years. The diagnosis of BP was diagnosed based on the results of biopsy immunohistochemistry and serum antibodies, and the baseline BPDAI score was 18. The patient was treated with dupriuzumab, and the initial dose was 600 mg ,then 300 mg was given after 2 weeks. The lesions subsided and  pigmentation remained 3 weeks after the second dose, and the BPDAI score decreased to 4. The patient did not relapse after 3 months of follow-up.

Key words: bullous pemphigoid, dupilumab